See more : OYAK Çimento Fabrikalari A.S. (OYAKC.IS) Income Statement Analysis – Financial Results
Complete financial analysis of Kyowa Kirin Co., Ltd. (KYKOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kyowa Kirin Co., Ltd., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Janus International Group, Inc. (JBI) Income Statement Analysis – Financial Results
- Ruchi Infrastructure Limited (RUCHINFRA.BO) Income Statement Analysis – Financial Results
- GoviEx Uranium Inc. (GXU.V) Income Statement Analysis – Financial Results
- Telecomunicações Brasileiras S.A. – Telebras (TELB4.SA) Income Statement Analysis – Financial Results
- First Responder Technologies Inc. (WPNNF) Income Statement Analysis – Financial Results
Kyowa Kirin Co., Ltd. (KYKOF)
About Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 442.23B | 398.37B | 352.25B | 318.35B | 305.82B | 346.53B | 353.38B | 343.02B | 364.32B | 333.45B | 340.61B | 333.16B | 343.72B | 413.74B | 0.00 | 392.12B | 354.27B | 353.44B | 358.96B | 348.84B | 359.29B | 378.67B | 375.61B | 374.91B |
| Cost of Revenue | 111.21B | 86.92B | 87.85B | 80.44B | 79.62B | 119.34B | 129.06B | 134.53B | 138.92B | 127.54B | 127.85B | 122.47B | 146.17B | 222.76B | 0.00 | 247.20B | 222.85B | 226.46B | 226.85B | 219.33B | 232.96B | 249.92B | 251.67B | 248.04B |
| Gross Profit | 331.03B | 311.46B | 264.40B | 237.91B | 226.20B | 227.19B | 224.32B | 208.49B | 225.39B | 205.90B | 212.76B | 210.69B | 197.56B | 190.98B | 0.00 | 144.92B | 131.43B | 126.98B | 132.11B | 129.51B | 126.33B | 128.74B | 123.95B | 126.87B |
| Gross Profit Ratio | 74.85% | 78.18% | 75.06% | 74.73% | 73.97% | 65.56% | 63.48% | 60.78% | 61.87% | 61.75% | 62.46% | 63.24% | 57.48% | 46.16% | 0.00% | 36.96% | 37.10% | 35.93% | 36.80% | 37.13% | 35.16% | 34.00% | 33.00% | 33.84% |
| Research & Development | 81.51B | 62.90B | 57.68B | 52.31B | 53.51B | 48.59B | 49.16B | 53.79B | 51.52B | 47.67B | 43.63B | 44.78B | 47.93B | 44.06B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 133.23B | 166.19B | 145.61B | 126.61B | 117.32B | 119.81B | 112.96B | 0.00 | 0.00 | 169.00M | 205.00M | 145.00M | 132.00M | 0.00 | 0.00 | 105.53B | 100.73B | 101.45B | 98.61B | 102.67B | 110.24B | 108.39B | 106.23B | 105.22B |
| Selling & Marketing | 29.85B | 47.33B | 38.56B | 30.28B | 24.03B | 19.48B | 13.71B | 15.86B | 16.71B | 15.96B | 16.42B | 15.19B | 15.27B | 15.66B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 163.08B | 166.19B | 145.61B | 126.61B | 117.32B | 119.81B | 112.96B | 15.86B | 16.71B | 15.96B | 16.42B | 15.19B | 15.40B | 15.66B | 0.00 | 105.53B | 100.73B | 101.45B | 98.61B | 102.67B | 110.24B | 108.39B | 106.23B | 105.22B |
| Other Expenses | 0.00 | -21.36B | -5.63B | -9.19B | -14.58B | 15.50B | -1.76B | 753.00M | 255.00M | -141.00M | -392.00M | -1.00M | -124.00M | 1.13B | 0.00 | -2.05B | 0.00 | -1.47B | -4.05B | -11.44B | 0.00 | -5.61B | 6.09B | 2.06B |
| Operating Expenses | 244.59B | 229.08B | 203.29B | 178.92B | 170.83B | 168.40B | 162.11B | 176.85B | 181.62B | 169.73B | 160.98B | 157.78B | 112.90B | 106.73B | 0.00 | 105.53B | 100.73B | 101.45B | 98.61B | 102.67B | 110.24B | 108.39B | 106.23B | 105.22B |
| Cost & Expenses | 355.79B | 316.00B | 291.14B | 259.36B | 250.45B | 287.74B | 291.17B | 311.38B | 320.55B | 297.27B | 288.83B | 280.25B | 259.06B | 329.49B | 0.00 | 352.73B | 323.58B | 327.91B | 325.46B | 322.00B | 343.20B | 358.31B | 357.90B | 353.25B |
| Interest Income | 4.87B | 3.32B | 1.11B | 1.80B | 1.03B | 839.00M | 806.00M | 476.00M | 459.00M | 629.00M | 775.00M | 604.00M | 497.00M | 362.00M | 0.00 | 1.80B | 528.00M | 1.17B | 995.00M | 686.00M | 781.00M | 778.00M | 827.00M | 798.00M |
| Interest Expense | 190.00M | 1.09B | 1.12B | 299.00M | 1.31B | 1.59B | 931.00M | 42.00M | 59.00M | 145.00M | 259.00M | 205.00M | 135.00M | 199.00M | 0.00 | 328.00M | 240.00M | 186.00M | 240.00M | 804.00M | 1.72B | 3.11B | 3.13B | 2.72B |
| Depreciation & Amortization | 17.19B | 18.48B | 19.50B | 20.47B | 18.80B | 16.24B | 22.03B | 23.78B | 36.56B | 36.71B | 33.17B | 32.93B | 33.55B | 32.12B | 0.00 | 14.35B | 10.01B | 9.79B | 10.57B | 11.36B | 14.77B | 17.82B | 18.50B | 19.38B |
| EBITDA | 113.04B | 87.14B | 79.86B | 74.71B | 70.83B | 84.47B | 84.53B | 67.06B | 80.33B | 72.88B | 84.94B | 78.16B | 79.86B | 74.61B | 0.00 | 60.10B | 53.49B | 33.77B | 34.85B | 40.71B | 33.54B | 33.48B | 33.40B | 43.51B |
| EBITDA Ratio | 25.56% | 21.87% | 22.90% | 22.94% | 21.12% | 28.06% | 22.30% | 18.87% | 20.76% | 20.35% | 24.64% | 25.15% | 34.51% | 28.44% | 0.00% | 14.45% | 11.34% | 10.50% | 12.66% | 15.05% | 9.34% | 13.98% | 13.41% | 11.48% |
| Operating Income | 86.44B | 68.66B | 61.17B | 52.56B | 45.80B | 75.03B | 57.73B | 31.64B | 43.77B | 36.17B | 51.77B | 52.91B | 85.08B | 45.41B | 0.00 | 39.39B | 30.16B | 25.54B | 33.51B | 26.84B | 18.78B | 20.36B | 17.71B | 21.66B |
| Operating Income Ratio | 19.55% | 17.24% | 17.36% | 16.51% | 14.98% | 21.65% | 16.34% | 9.22% | 12.01% | 10.85% | 15.20% | 15.88% | 24.75% | 10.98% | 0.00% | 10.05% | 8.51% | 7.22% | 9.33% | 7.69% | 5.23% | 5.38% | 4.72% | 5.78% |
| Total Other Income/Expenses | 10.81B | 2.76B | -1.06B | -299.00M | -1.31B | -1.59B | -1.88B | -1.35B | -2.37B | -8.93B | -2.00B | -7.88B | -38.89B | -3.11B | 0.00 | -14.45B | -575.00M | -2.01B | -663.00M | -3.60B | -3.40B | 904.00M | -7.90B | 215.00M |
| Income Before Tax | 97.25B | 67.57B | 60.05B | 52.26B | 44.49B | 73.44B | 55.85B | 30.29B | 41.40B | 27.25B | 49.77B | 45.03B | 46.18B | 42.30B | 0.00 | 38.82B | 23.53B | 24.87B | 29.90B | 15.38B | 16.99B | 12.46B | 21.87B | 22.58B |
| Income Before Tax Ratio | 21.99% | 16.96% | 17.05% | 16.42% | 14.55% | 21.19% | 15.80% | 8.83% | 11.36% | 8.17% | 14.61% | 13.51% | 13.44% | 10.22% | 0.00% | 9.90% | 6.64% | 7.04% | 8.33% | 4.41% | 4.73% | 3.29% | 5.82% | 6.02% |
| Income Tax Expense | 16.06B | 14.00B | 7.70B | 5.24B | 6.82B | 19.03B | 12.95B | 11.62B | 11.63B | 11.35B | 19.60B | 20.61B | 20.49B | 20.04B | 0.00 | 15.19B | 10.87B | 8.49B | 11.90B | 5.53B | 8.48B | 6.99B | 12.74B | 11.49B |
| Net Income | 81.19B | 53.57B | 52.35B | 47.03B | 67.08B | 54.41B | 42.90B | 18.67B | 29.77B | 15.90B | 30.08B | 24.20B | 25.61B | 22.20B | 0.00 | 23.48B | 12.69B | 16.27B | 17.93B | 10.02B | 8.49B | 5.54B | 9.40B | 11.27B |
| Net Income Ratio | 18.36% | 13.45% | 14.86% | 14.77% | 21.94% | 15.70% | 12.14% | 5.44% | 8.17% | 4.77% | 8.83% | 7.26% | 7.45% | 5.36% | 0.00% | 5.99% | 3.58% | 4.60% | 5.00% | 2.87% | 2.36% | 1.46% | 2.50% | 3.01% |
| EPS | 151.01 | 99.68 | 97.43 | 87.56 | 124.57 | 100.95 | 78.38 | 34.11 | 54.40 | 29.05 | 54.95 | 44.12 | 45.16 | 38.96 | 0.00 | 59.03 | 31.32 | 38.48 | 41.93 | 23.21 | 19.56 | 12.75 | 21.64 | 25.96 |
| EPS Diluted | 151.01 | 99.66 | 97.39 | 87.50 | 124.46 | 100.95 | 78.30 | 34.08 | 54.36 | 29.02 | 54.91 | 44.10 | 45.14 | 38.94 | 0.00 | 59.03 | 31.32 | 38.30 | 41.93 | 23.21 | 19.56 | 12.75 | 21.64 | 25.90 |
| Weighted Avg Shares Out | 537.63M | 537.43M | 537.27M | 537.11M | 538.54M | 539.01M | 547.29M | 547.29M | 547.29M | 547.35M | 547.39M | 548.45M | 567.03M | 569.71M | 570.94M | 397.72M | 405.27M | 422.92M | 427.64M | 431.50M | 433.75M | 434.24M | 434.24M | 434.24M |
| Weighted Avg Shares Out (Dil) | 537.63M | 537.57M | 537.51M | 537.48M | 539.01M | 539.01M | 547.86M | 547.86M | 547.72M | 547.83M | 547.77M | 548.73M | 567.30M | 570.03M | 570.94M | 397.72M | 405.27M | 424.88M | 427.64M | 431.50M | 433.75M | 434.24M | 434.24M | 435.29M |
Kyowa Kirin Announces Acceptance of Abstract for Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting 2024
Kyowa Kirin's gene therapy most expensive US drug with $4.3 mln price tag
Kyowa Kirin Will Present Phase 2b Post-hoc Analysis and Symposium at the American Academy of Dermatology Annual Meeting 2024
Kyowa Kirin Announce Symposium, Acceptance of Abstract for Presentation at American Academy of Dermatology 2024 Meeting
Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema
Kyowa Kirin Responds to NICE's Publication of Appraisal Consultation Document for CRYSVITA® (Burosumab), for Treatment of Rare Disease X-Linked Hypophosphataemia (XLH) in Adults1
Kyowa Kirin Presents Real-World Findings at ASBMR Annual Meeting Highlighting Progressive Disease Burden of X-linked Hypophosphatemia (XLH)
Kyowa Kirin to Present New Research on X-linked Hypophosphatemia (XLH) at ASBMR Annual Meeting
Kyowa Kirin Announces Three Abstracts and A Symposium at the European Academy of Dermatology and Venereology Congress 2023
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln
Source: https://incomestatements.info
Category: Stock Reports